Comparatively, ICC 2022 classification mandates a blast count cutoff of 10% for diagnosing AML with recurrent genetic abnormalities, except for AML with (BCR;ABL1) fusion, which still requires a 20% blast threshold. Here, ABL1 is linked to acute myeloid leukemia.